Last updated on September 2018

A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer

Brief description of study

This is a global Phase III, double-blind, randomized, placebo-controlled study designed to evaluate the efficacy and safety of neoadjuvant treatment with atezolizumab (anti-programmed death-ligand 1 [anti-PD-L1] antibody) and nab-paclitaxel followed by doxorubicin and cyclophosphamide (nab-pac-AC), or placebo and nab-pacAC in participants eligible for surgery with initial clinically assessed triple-negative breast cancer (TNBC).

Clinical Study Identifier: NCT03197935

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: WO39392 ...

Luisenkrankenhaus GmbH, Brustzentrum
Düsseldorf, Germany
  Connect »